State-of-the-art cerium nanoparticles as promising agents against human viral infections.
Adjuvant
Cerium nanoparticle
Vaccine
Viral Infections
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
05
09
2022
revised:
10
10
2022
accepted:
13
10
2022
pubmed:
19
10
2022
medline:
23
11
2022
entrez:
18
10
2022
Statut:
ppublish
Résumé
The world is faces a significant global health challenge in the form of viral infections, particularly the emergence of viral strains that are resistant to effective antiviral therapies. This underscores the urgent need for the development of effective and safe antiviral agents. Nanoscale materials are now being used as novel antiviral agents. Cerium nanoparticles have unique chemical and physical properties that make them particularly promising for viral infections. These particles reduce inflammation and the autoimmune response. Cerium nanoparticles, in addition to their antiviral properties, have many other advantages that are highly sought after for various aspects of biomedical applications. This review focuses on the various properties of cerium nanoparticles as a novel agent against viral infections.
Identifiants
pubmed: 36257210
pii: S0753-3322(22)01257-4
doi: 10.1016/j.biopha.2022.113868
pii:
doi:
Substances chimiques
Cerium
30K4522N6T
Antioxidants
0
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
113868Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare no conflict of interest for manuscript entitled “State-of-the-art cerium nanoparticles as promising tools against human viral infections”.